Physician profile
Carl Goolsby
NPI 1174505390
$949.63
in general payments reported to CMS, 2019-2025
24 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.20 · 2020: $24.63 · 2021: $89.09 · 2022: $194 · 2023: $180 · 2024: $198 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $91.61 | 2022-2025 | Wegovy |
| Dexcom, INC. | $86.54 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $83.99 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $80.15 | 2020-2024 | Proclaim |
| Glaxosmithkline, LLC. | $70.45 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $62.41 | 2022-2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $57.45 | 2024-2025 | |
| Pfizer INC. | $44.94 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.71 | 2021-2024 | Xifaxan |
| Boston Scientific Corporation | $34.57 | 2025 | General - Pain Management |
| Astellas Pharma US INC | $32.14 | 2023 | Myrbetriq, Veozah |
| Abbvie INC. | $28.37 | 2022-2023 | |
| Inspire Medical Systems, INC. | $27.81 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.64 | 2024 | |
| Horizon Therapeutics Plc | $22.38 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $22.08 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.21 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $21.12 | 2022 | |
| Genzyme Corporation | $20.21 | 2024 | |
| Biotronik Nro, INC. | $18.13 | 2025 | Prospera |
| Sanofi-Aventis U.S. LLC | $15.67 | 2025 | |
| Exact Sciences Corporation | $15.44 | 2023 | Cologuard Collection Kit |
| Ardelyx, INC. | $13.16 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Goolsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.